Literature DB >> 14585981

Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene.

Natalia Ninkina1, Katerina Papachroni, Darren C Robertson, Oliver Schmidt, Liz Delaney, Francis O'Neill, Felipe Court, Arnon Rosenthal, Susan M Fleetwood-Walker, Alun M Davies, Vladimir L Buchman.   

Abstract

Homologous recombination in ES cells was employed to generate mice with targeted deletion of the first three exons of the gamma-synuclein gene. Complete inactivation of gene expression in null mutant mice was confirmed on the mRNA and protein levels. Null mutant mice are viable, are fertile, and do not display evident phenotypical abnormalities. The effects of gamma-synuclein deficiency on motor and peripheral sensory neurons were studied by various methods in vivo and in vitro. These two types of neurons were selected because they both express high levels of gamma-synuclein from the early stages of mouse embryonic development but later in the development they display different patterns of intracellular compartmentalization of the protein. We found no difference in the number of neurons between wild-type and null mutant animals in several brain stem motor nuclei, in lumbar dorsal root ganglia, and in the trigeminal ganglion. The survival of gamma-synuclein-deficient trigeminal neurons in various culture conditions was not different from that of wild-type neurons. There was no difference in the numbers of myelinated and nonmyelinated fibers in the saphenous nerves of these animals, and sensory reflex thresholds were also intact in gamma-synuclein null mutant mice. Nerve injury led to similar changes in sensory function in wild-type and mutant mice. Taken together, our data suggest that like alpha-synuclein, gamma-synuclein is dispensable for the development and function of the nervous system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585981      PMCID: PMC262405          DOI: 10.1128/MCB.23.22.8233-8245.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  57 in total

1.  Persyn, a member of the synuclein family, influences neurofilament network integrity.

Authors:  V L Buchman; J Adu; L G Pinõn; N N Ninkina; A M Davies
Journal:  Nat Neurosci       Date:  1998-06       Impact factor: 24.884

2.  Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology.

Authors:  J E Galvin; B Giasson; H I Hurtig; V M Lee; J Q Trojanowski
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

Authors:  N Ostrerova-Golts; L Petrucelli; J Hardy; J M Lee; M Farer; B Wolozin
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

4.  Chicken synucleins: cloning and expression in the developing embryo.

Authors:  A A Tiunova; K V Anokhin; A R Saha; O Schmidt; D P Hanger; B H Anderton; A M Davies; N N Ninkina; V L Buchman
Journal:  Mech Dev       Date:  2000-12       Impact factor: 1.882

5.  The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy.

Authors:  T Dickinson; R Mitchell; P Robberecht; S M Fleetwood-Walker
Journal:  Neuropharmacology       Date:  1999-01       Impact factor: 5.250

6.  Induction of neuronal death by alpha-synuclein.

Authors:  A R Saha; N N Ninkina; D P Hanger; B H Anderton; A M Davies; V L Buchman
Journal:  Eur J Neurosci       Date:  2000-08       Impact factor: 3.386

7.  Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity.

Authors:  S J Tabrizi; M Orth; J M Wilkinson; J W Taanman; T T Warner; J M Cooper; A H Schapira
Journal:  Hum Mol Genet       Date:  2000-11-01       Impact factor: 6.150

8.  Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs.

Authors:  A L Biere; S J Wood; J Wypych; S Steavenson; Y Jiang; D Anafi; F W Jacobsen; M A Jarosinski; G M Wu; J C Louis; F Martin; L O Narhi; M Citron
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

Review 9.  Synucleinopathies: clinical and pathological implications.

Authors:  J E Galvin; V M Lee; J Q Trojanowski
Journal:  Arch Neurol       Date:  2001-02

10.  Conformational properties of alpha-synuclein in its free and lipid-associated states.

Authors:  D Eliezer; E Kutluay; R Bussell; G Browne
Journal:  J Mol Biol       Date:  2001-04-06       Impact factor: 5.469

View more
  43 in total

1.  Hindering of proteinopathy-induced neurodegeneration as a new mechanism of action for neuroprotectors and cognition enhancing compounds.

Authors:  S O Bachurin; A A Ustyugov; O Peters; T A Shelkovnikova; V L Buchman; N N Ninkina
Journal:  Dokl Biochem Biophys       Date:  2009 Sep-Oct       Impact factor: 0.788

2.  Protein aggregation in retinal cells and approaches to cell protection.

Authors:  Irina Surgucheva; Natalia Ninkina; Vladimir L Buchman; Kenneth Grasing; Andrei Surguchov
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

3.  αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction.

Authors:  Becket Greten-Harrison; Manuela Polydoro; Megumi Morimoto-Tomita; Ling Diao; Andrew M Williams; Esther H Nie; Sachin Makani; Ning Tian; Pablo E Castillo; Vladimir L Buchman; Sreeganga S Chandra
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

4.  Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein.

Authors:  Ken Nakamura; Venu M Nemani; Farnaz Azarbal; Gaia Skibinski; Jon M Levy; Kiyoshi Egami; Larissa Munishkina; Jue Zhang; Brooke Gardner; Junko Wakabayashi; Hiromi Sesaki; Yifan Cheng; Steven Finkbeiner; Robert L Nussbaum; Eliezer Masliah; Robert H Edwards
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

5.  Hypokinesia and reduced dopamine levels in zebrafish lacking β- and γ1-synucleins.

Authors:  Chiara Milanese; Jonathan J Sager; Qing Bai; Thomas C Farrell; Jason R Cannon; J Timothy Greenamyre; Edward A Burton
Journal:  J Biol Chem       Date:  2011-11-29       Impact factor: 5.157

6.  Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma.

Authors:  Judy V Nguyen; Ileana Soto; Keun-Young Kim; Eric A Bushong; Ericka Oglesby; Francisco J Valiente-Soriano; Zhiyong Yang; Chung-ha O Davis; Joseph L Bedont; Janice L Son; John O Wei; Vladimir L Buchman; Donald J Zack; Manuel Vidal-Sanz; Mark H Ellisman; Nicholas Marsh-Armstrong
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-03       Impact factor: 11.205

7.  Differential expression of sarcoplasmic and myofibrillar proteins of rat soleus muscle during denervation atrophy.

Authors:  Yusuke Sato; Motoyuki Shimizu; Wataru Mizunoya; Hiroyuki Wariishi; Ryuichi Tatsumi; Vladimir L Buchman; Yoshihide Ikeuchi
Journal:  Biosci Biotechnol Biochem       Date:  2009-08-07       Impact factor: 2.043

8.  Localization of synucleins in the mammalian cochlea.

Authors:  O Akil; C M Weber; S N Park; N Ninkina; V Buchman; L R Lustig
Journal:  J Assoc Res Otolaryngol       Date:  2008-07-30

9.  Targets of tyrosine nitration in diabetic rat retina.

Authors:  Xianquan Zhan; Yunpeng Du; John S Crabb; Xiaorong Gu; Timothy S Kern; John W Crabb
Journal:  Mol Cell Proteomics       Date:  2007-12-28       Impact factor: 5.911

10.  Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein.

Authors:  Natalia Ninkina; Owen Peters; Steven Millership; Hatem Salem; Herman van der Putten; Vladimir L Buchman
Journal:  Hum Mol Genet       Date:  2009-02-26       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.